Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05191446 · ClinicalTrials.gov registry record · NA
Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use
A NA study of Alcohol Use Disorder and Liver Diseases, sponsored by University of California, San Francisco.
- Active
- Registry status
- NA
- Development phase
- 180
- Enrollment target
- 2
- Study locations
NCT05191446 is a NA study of Alcohol Use Disorder and Liver Diseases that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 180 participants, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05191446, a NA study of Alcohol Use Disorder and Liver Diseases, is active but no longer recruiting, sponsored by University of California, San Francisco.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 180 participants
- Enrollment target
- 2
- Study locations
Study Summary
The study consists of a randomized controlled trial evaluating the efficacy and feasibility of a stepped alcohol treatment using telemedicine on unhealthy alcohol use in patients with chronic liver disease receiving care in hepatology practices at three sites. Patients who meet eligibility criteria will be randomized to one of two study arms: 1) Stepped Alcohol Treatment (SAT) or, 2) Usual Care (UC). Participants will be randomized separately by site. SAT includes 3 sessions of motivational interviewing followed by referral to addiction medicine for patients who do not reduce unhealthy drinking. Trial outcome measures will be complete at 6 and 12 months following baseline enrollment.
Conditions Studied
Interventions
- BEHAVIORAL Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use
- OTHER Usual Care (UC)
Study Locations (2)
California
- University of california San Francisco - San Francisco
- Zuckerberg San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2022-02-01 |
| Est. Completion | 2026-02-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05191446
The ClinicalTrials.gov registry entry for NCT05191446 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 327-participant average among 184 other Alcohol Use Disorder trials with a reported enrollment target (45% lower). The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Alcohol Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use is the first listed.
NCT05191446 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT05191446 about?
NCT05191446 is a clinical study titled "Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use". The study consists of a randomized controlled trial evaluating the efficacy and feasibility of a stepped alcohol treatment using telemedicine on unhealthy alcohol use in patients with chronic liver disease receiving care in hepatology practices at three sites. Patients who meet eligibility criteria ...
What is the current status of trial NCT05191446?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 180 participants. The study started on 2022-02-01. Estimated completion is 2026-02-27.
What conditions does trial NCT05191446 study?
This clinical trial studies the following conditions: Alcohol Use Disorder, Liver Diseases.
What interventions are being tested in trial NCT05191446?
The interventions under investigation include: Stepped alcohol intervention (SAT) to reduce unhealthy alcohol use (BEHAVIORAL), Usual Care (UC) (OTHER).
Who is sponsoring clinical trial NCT05191446?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05191446 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol Use Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ultrasound Neuromodulation of the Brain for Alcohol Use Disorder
RECRUITING · NA
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Integrated Treatment for Enhancing Growth in Recovery During Adolescence
RECRUITING · NA
-
AAT for Alcohol Use Disorder in Veterans
RECRUITING · NA
-
Testing a PTSD m-Health Intervention to Improve Alcohol Treatment Outcomes
RECRUITING · NA
-
Validating an Autonomous Interactive Internet-Based Delivery of an Empirically Supported Cognitive Behavioral Therapy for Comorbidity
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.